HSPG2 is represented in the stroma of several tumor types [97], where it is predicted to bind tenascin C and modify growth factor signaling, including VEGF and FGF, by increasing the binding of these ligands to their receptors [98,99]. Here, VEGFA is linked to neoplasm.